Background: Low-dose acetylsalicylic acid (ASA) is the mainstay of cardiovascular (CV) disease management, but may be associated with peptic ulcers (PU) and adverse upper gastrointestinal (GI) symptoms, which may lead to cessation of therapy. This post-hoc subanalysis of the OBERON study (NCT00441727; 204 centers in 20 countries) assessed the efficacy of esomeprazole (ESO) 20 and 40 mg once daily (qd) in reduction of PU and dyspeptic symptoms, stratified by ASA dose (75-100 mg or 101-325 mg qd).
